J Korean Androl Soc.  1997 Jun;15(1):71-76.

Results of High Energy Transurethral Microwave Thermotherapy in Benign Prostatic Hyperplasia

• Seo KK
• Ahn SY
• Moon YT
• Kim KD
• Kim SC

Abstract

PURPOSE: To analyze the clinical efficacy and safety of high-energy transurthral microwave thermotherapy (TUMT) using the Prostasoft 2.5 in the patients with benign prostatic hyperplasia (BPH).
PATIENTS AND METHODS
Patients with a Madsen symptom score (Mss) and international Prostatic symptom score (IPSS) of 8 or more and peak flow rare (PFR) 15 ml per second or less were treated. Ninety-four patients (mean age 66.0 years; range: 54-91 years) were followed for at least 1 month. The MSS, IPSS, mean PFR (Qmax), and postvoiding residual volume (PVR) were measured at baseline and 1, 3, and 6 months after the treatment. An average of 140 kJ (range 83-496 kJ) of microwave energy was administered during the treatment. All patients had an indwelling urethral catheter for a week after the treatment.
RESULTS
Significant improvement (p<0.01) was noted in all subjective (MSS and IPSS) and objective (Qmax and PVR) measures at 1, 3, and 6 months. The most common side effect of TUMT was urethral catheter at 1 week, in 29 (31%), and gross hematuria for longer than 2 days, in 22 (23%).
CONCLUSION
High-energy TUMT would be an effective and safe method for the treatment of symptomatic BPH. Further studies are necessary on the long-term outcome of this procedure.

MeSH Terms

Fever
Hematuria
Humans
Hyperthermia, Induced
Microwaves
Prostatic Hyperplasia*
Residual Volume
Transurethral Resection of Prostate*
Urinary Catheters